TLR8 and neoplasm: To further investigate the unique downstream signaling pathway of TLR8 responsible for the control of the capacity of tumor-induced T-cell senescence, we still utilized loss-of-function strategies involving both specific pharmacological inhibitors and siRNA to block NF-κB and MAPK signaling pathways (JNK, ERK1/2 and p38) in tumor cells.